Belimumab ameliorates symptoms and disease activity in dermatomyositis and juvenile dermatomyositis patients refractory to standard therapy: a retrospective observational study

J Am Acad Dermatol. 2024 Apr 30:S0190-9622(24)00682-0. doi: 10.1016/j.jaad.2024.04.060. Online ahead of print.
No abstract available

Keywords: B cell activating factor (BAFF); B lymphocyte stimulator (BLyS); Myositis Intention-to-Treat Activity Index (MITAX); belimumab; dermatomyositis; juvenile dermatomyositis.